What is a BCR-ABL1 genetic test? A BCR-ABL1 genetic test uses a sample of blood or bone marrow to look for an abnormal gene called BCR-ABL1. This abnormal gene is involved in certain types of blood cancer. It's found in: Most people who have chronic myeloid leukemia (CML), which is also called chronic granulocytic leukemia or chronic myeloid ...

2025年3月3日 · Simply put, BCR-ABL1 is an oncogene, a mutated gene that can cause cancer. BCR-ABL1 forms when two of your chromosomes accidentally swap DNA during cell division. When this occurs, the ABL1...

The BCR-ABL test stands as a pivotal tool in the diagnosis and management of chronic myeloid leukemia. Its ability to pinpoint the presence of the BCR-ABL fusion gene offers insights into disease progression, guiding tailored treatment plans and fostering better patient outcomes.

BCR::ABL1 (BCR-ABL1) testing is recommended for patients with either chronic myeloid leukemia (CML), a hematopoietic stem cell disease, or acute lymphoblastic leukemia (ALL), an aggressive type of leukemia of either B- or T-lineage immature lymphoid cells.

This assay can detect three different types of BCR-ABL1 fusion transcripts associated with CML, ALL, and AML:e13a2 (previously b2a2) and e14a2 (previously b3a2) (major breakpoint, p210), as well as e1a2 (minor breakpoint, p190). The e13a2 and e14a2 transcript values are titrated to the current International Scale (IS).

A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals.

2020年11月6日 · BCR-ABL1 testing detects the presence of the BCR-ABL1 gene sequence in an abnormal chromosome 22 to help diagnose chronic myelogenous leukemia and a form of acute lymphoblastic lymphoma.

Other names: BCR-ABL1, BCR-ABL1 fusion, Philadelphia chromosome What is it used for? A BCR-ABL test is most often used to diagnose or rule out chronic myeloid leukemia (CML) or a specific form of acute lymphoblastic leukemia (ALL) called Ph-positive ALL.

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-normal life expectancy.

Quantitative reverse-transcription polymerase chain reaction is the most sensitive method for monitoring BCR-ABL1 levels during treatment. This test detects the BCR/ABL1 mRNA fusion forms found in CML (e13/a2 and e14/a2).